百济神州(06160.HK)公布年度业绩 产品收入增加约72.6% 预计2025年在美国公认会计原则下实现经营利润

Core Insights - Company reported a revenue increase of approximately $1.4 billion or about 55.0$3.8 billion for the fiscal year ending December 31, 2024 [1] - Product revenue rose by approximately $1.6 billion or about 72.6$236.9 million or about 26.9% to around $644.8 million [1] Financial Performance - Adjusted gross margin for product sales improved, with cash and cash equivalents reaching$2.6 billion as of December 31, 2024 [1] - Since 2023, the current product portfolio and core product revenue have grown by 73%, with expectations for significant growth in product revenue in 2025 and beyond [1] - Research and development expenses increased by $174.7 million or 9.8$2 billion for the fiscal year ending December 31, 2024 [1] Market Position - The company's strong annual performance highlights its position as a global leader in cancer treatment, driven by the ongoing success of its flagship product and a robust pipeline in oncology [1] - Multiple projects are expected to advance in 2025, indicating a promising outlook for the company's future growth in the oncology sector [1]